The -c(=x)- Is Part Of A -c(=x)x- Group, Wherein The X's Are The Same Or Diverse Chalcogens Patents (Class 549/71)
-
Publication number: 20090275646Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.Type: ApplicationFiled: April 21, 2009Publication date: November 5, 2009Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
-
Publication number: 20090270387Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, and B are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: April 22, 2009Publication date: October 29, 2009Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Jeremiah H. Nguyen
-
Publication number: 20090270385Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein G, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: April 22, 2009Publication date: October 29, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Vinh X. Ngo
-
Publication number: 20090270386Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein G, B, D, and Y are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: April 22, 2009Publication date: October 29, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Vinh X. NGO
-
Publication number: 20090239858Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein G, E, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: March 16, 2009Publication date: September 24, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Robert M. Burk, Todd Gac
-
Patent number: 7592366Abstract: A compound having a formula is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: July 10, 2007Date of Patent: September 22, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Vinh X. Ngo
-
Publication number: 20090233921Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, and B are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: March 6, 2009Publication date: September 17, 2009Applicant: ALLERGAN, INC.Inventor: Yariv Donde
-
Publication number: 20090227573Abstract: Disclosed herein are compounds represented by the formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: February 25, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner, Yariv Donde, David W. Old
-
Publication number: 20090192151Abstract: Disclosed herein are compounds useful in treating glaucoma, inflammatory bowel disease, the stimulation of hair growth, and the stimulation of the conversion of vellus hair to terminal hair. The compounds themselves are herein.Type: ApplicationFiled: January 14, 2009Publication date: July 30, 2009Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090186885Abstract: Disclosed herein is a compound according to one of the formulas wherein R Additionally, pharmaceutically acceptable salt thereof, and methods of treating disease, medicaments, and compositions related thereto, are further elaborated herein.Type: ApplicationFiled: January 13, 2009Publication date: July 23, 2009Inventors: Brent A. Johnson, David W. Old, Yariv Donde, Robert M. Burk
-
Publication number: 20090143461Abstract: Disclosed herein are compounds having a formula: Therapeutic methods, medicaments, and compositions related thereto are also disclosed.Type: ApplicationFiled: November 24, 2008Publication date: June 4, 2009Inventor: Robert M. Burk
-
Publication number: 20090137822Abstract: The present invention relates to a process for preparing a 3-substituted thiophene represented by the formula (2): wherein R represents a cyano group, a formyl group, a carboxyl group, a hydrocarbyloxycarbonyl group which may have a substituent(s) or an acyl group which may have a substituent(s), which comprises reacting a vinyl compound represented by the formula (1): RCH?CHY??(1) wherein R has the same meaning as defined above, and Y represents a leaving group, and an ?-mercaptoacetaldehyde or a multimer thereof.Type: ApplicationFiled: May 16, 2006Publication date: May 28, 2009Inventors: Akio Matsushita, Kiyotaka Yoshii, Mizuho Oda, Masayoshi Oue, Shuji Yamada
-
Publication number: 20090124676Abstract: Disclosed herein are compounds having a formula: Therapeutic methods, medicaments, and compositions related thereto are also disclosed.Type: ApplicationFiled: November 5, 2008Publication date: May 14, 2009Inventor: Yariv Donde
-
Patent number: 7528274Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.Type: GrantFiled: July 25, 2002Date of Patent: May 5, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: John K. Inman, Atul Goel, Ettore Appella, Jim Turpin, Marco Schito
-
Publication number: 20090105280Abstract: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.Type: ApplicationFiled: September 20, 2006Publication date: April 23, 2009Applicant: REVOTAR BIOPHARMACEUTICALS AGInventors: Ewald M. Aydt, Remo Kranich
-
Patent number: 7521473Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.Type: GrantFiled: February 23, 2005Date of Patent: April 21, 2009Assignee: WyethInventors: Jinbo Lee, Zhao-Kui Wan, Douglas P. Wilson, Bruce C. Follows, Steven J. Kirincich, Michael J. Smith, Jun-Jun Wu, Kenneth W. Foreman, David V. Erbe, Yan-Ling Zhang, Weixin Xu, Steve Y. Tam
-
Publication number: 20090018168Abstract: Disclosed herein is a compound having a formula therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: April 29, 2008Publication date: January 15, 2009Inventors: David W. Old, Vinh X. Ngo
-
Publication number: 20090018104Abstract: Provided is a triarylcarboxylic acid derivative, or an isomer, a prodrug, a hydrate, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I): wherein A is an optionally substituted aryl or heteroaryl, and B is an optionally substituted monocyclic heteroaryl; and a pharmaceutical composition comprising the same and a pharmaceutically acceptable carrier. The triarylcarboxylic acid derivative (I) exhibits potent xanthine oxidase inhibiting action and is therefore useful as a therapeutic agent for preventing or treating hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy and diabetic retinopathy.Type: ApplicationFiled: October 6, 2006Publication date: January 15, 2009Applicant: Astellas Pharma Inc.Inventors: Junji Sato, Kazuyuki Hattori, Hirokazu Kubota, Ryosuke Munakata, Toru Asano, Junko Maeda, Masakatsu Kawakami, Akio Kamikawa
-
Patent number: 7468360Abstract: Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.Type: GrantFiled: August 8, 2007Date of Patent: December 23, 2008Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20080312321Abstract: Therapeutic compounds are disclosed herein.Type: ApplicationFiled: August 14, 2008Publication date: December 18, 2008Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Robert M. Burk
-
Publication number: 20080300269Abstract: Disclosed herein are compounds of the formula or salts or bioisosteres thereof. Therapeutic methods, medicaments, and compositions related thereto are also disclosed.Type: ApplicationFiled: August 6, 2008Publication date: December 4, 2008Applicant: ALLERGAN, INC.Inventors: David W. Old, Vinh X. Ngo
-
Patent number: 7439372Abstract: A compound having a structure is disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed.Type: GrantFiled: May 1, 2007Date of Patent: October 21, 2008Assignee: Allergan, Inc.Inventors: Donde Yariv, Jeremiah H. Nguyen
-
Patent number: 7427685Abstract: Therapeutic compounds according to one of the structures below are disclosed herein.Type: GrantFiled: October 26, 2006Date of Patent: September 23, 2008Assignee: Allergan, Inc.Inventors: Yariv Donde, Robert M. Burk
-
Publication number: 20080207741Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning —X— is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.Type: ApplicationFiled: September 20, 2006Publication date: August 28, 2008Applicant: REVOTAR BIOPHARMACEUTICALS AGInventors: Ewald M. Aydt, Remo Kranich
-
Publication number: 20080153850Abstract: The invention provides compounds of formula (I) pharmaceutically acceptable salt or solvate thereof, in which R1, A1, m and A are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.Type: ApplicationFiled: August 29, 2005Publication date: June 26, 2008Applicant: AstraZeneca ABInventors: Rhonan Ford, Barrie Martin, Toby Thompson, Nicholas Tomkinson, Paul Willis
-
Publication number: 20080015219Abstract: Disclosed and described herein are compounds of the formula or a pharmaceutically acceptable salt thereof, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed and described.Type: ApplicationFiled: May 14, 2007Publication date: January 17, 2008Inventors: DAVID W. OLD, VINH X. NGO
-
Publication number: 20080015231Abstract: A compound having a formula is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: July 10, 2007Publication date: January 17, 2008Inventors: David W. Old, Vinh X. Ngo
-
Patent number: 7317034Abstract: Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds, processes for their preparation, medicaments and pharmaceutical compositions containing them, and their use in treatment methods and in the preparation of analgesics, in the preparation of a local anaesthetic, an antiarrhythmic, an antiemetic, a nootropic agent and/or a medicament for the treatment and/or prophylaxis of cardiovascular diseases, urinary incontinence, diarrhea, pruritus and/or inflammations, and/or a medicament for the treatment of depression and/or alcohol and/or drug and/or medicament abuse, and/or a medicament for increasing vigilance.Type: GrantFiled: March 7, 2005Date of Patent: January 8, 2008Assignee: Gruenenthal GmbHInventors: Corrina Sundermann, Michael Przewosny
-
Patent number: 7247736Abstract: The present invention provides a compound capable of binding to the ubiquinone binding site of DHODH which contains a non-aromatic ring system as a core structure, a group capable of interacting with structural elements of subsite 2 or 3 of the ubiquinone binding site of DHODH and a group capable of interacting hydrophobically with structural elements of subsite 1 of the ubiquinone binding site of DHODH. Furthermore, the present invention provides a compound capable of binding to the ubiquinone binding site of DHODH which contains an aromatic ring system as a core structure, a group capable of interacting with residues His 56 and/or Tyr 356 of subsite 3 of the ubiquinone binding site of DHODH and a group capable of interacting hydrophobically with structural elements of subsite 1 of the ubiquinone binding site of DHODH.Type: GrantFiled: November 10, 2004Date of Patent: July 24, 2007Assignee: 4SC AGInventors: Johann Leban, Bernd Kramer, Roland Baumgartner, Katharina Aulinger-Fuchs, Stefan Tasler
-
Patent number: 7241795Abstract: The present invention relates to novel 2,5-bis{[alkyl (or aryl) imino]aminophenyl}furans and thiophenes of the general formula in which R1, R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups; R5 is H, alkyl or aryl; R6 is H, alkyl, aryl, or NR7R8, in which R7 and R8 are each independently selected from the group consisting of H, alkyl and aryl; and X is O, S or NR9, in which R9 is H or alkyl, and to the use of such compounds.Type: GrantFiled: March 2, 2004Date of Patent: July 10, 2007Assignees: The University of North Carolina at Chapel Hill, Georgia State University Research Foundation, Inc., Duke UniversityInventors: David W. Boykin, Richard R. Tidwell, W. David Wilson, John R. Perfect, Chad F. Stephens
-
Patent number: 7217295Abstract: The invention relates to the use of a composition comprising at least one conductive polymer in a cosmetically acceptable medium, said polymer being in soluble form in said medium, as, or for the manufacture of, cosmetic products for giving a visual effect to human keratin fibers and more particularly the hair, and also, when said conductive polymer absorbs in the visible region, as, or for the manufacture of, cosmetic products intended to color said fibers. The invention also relates to the corresponding treatment process.Type: GrantFiled: January 31, 2003Date of Patent: May 15, 2007Assignee: L'Oreal S.A.Inventors: Henri Samain, Grégory Plos, Nathalie Mougin
-
Patent number: 7211679Abstract: Semiconductor devices are described that include a semiconductor layer that comprises a perfluoroether acyl oligothiophene compound, preferably an ?,?-bis-perfluoroether acyl oligothiophene compound. Additionally, methods of making semiconductor devices are described that include depositing a semiconductor layer that contains a perfluoroether acyl oligothiophene compound, preferably an ?,?-bis(2-perfluoroether acyl oligothiophene compound.Type: GrantFiled: March 9, 2005Date of Patent: May 1, 2007Assignee: 3M Innovative Properties CompanyInventors: Christopher P. Gerlach, David A. Ender, Dennis E. Vogel
-
Patent number: 7129363Abstract: A conductive compound of formula (I) below, an electrode coated with the conductive compound, a sensor including the electrode, and a target molecule detection method using the sensor are provided: wherein Y is a carbonyl or —NH—; R is one of H, OH, a leaving group, and a probe group; l is an integer from 3 to 6; m is an integer from 1 to 4; and n is an integer from 0 to 3.Type: GrantFiled: March 1, 2004Date of Patent: October 31, 2006Assignee: Samsung Electronics Co., Ltd.Inventors: Jung-im Han, Jun-hoe Cha, Geun-bae Lim
-
Patent number: 7094911Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.Type: GrantFiled: October 31, 2002Date of Patent: August 22, 2006Assignee: Bayer AktiengesellschaftInventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
-
Patent number: 7034053Abstract: The present invention disclosed compounds of Formula I. The present invention also discloses beta-3 agonists of formula I and methods for treating beta-3 mediated diseases and condition using the compounds of formula I, in particular methods for treating diabetes or obesity.Type: GrantFiled: December 17, 2001Date of Patent: April 25, 2006Assignee: SmithKline Beecham CorporationInventors: David N. Deaton, Barry George Shearer, David Edward Uehling
-
Patent number: 7019024Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 9, 2001Date of Patent: March 28, 2006Assignee: Allelix Neuroscience Inc.Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
-
Patent number: 6982279Abstract: Compounds of the formulae IA and Ib. in which X, R(1), R(2), R(3), R(4), R(5), R(6), R(7), R(30) and R(31) have the meanings indicated in the claims, are very particularly suitable as novel antiarrhythmic active compounds, in particular for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutters.Type: GrantFiled: December 12, 2001Date of Patent: January 3, 2006Assignee: Aventis Pharm Deutschland GmbHInventors: Stefan Peukert, Joachim Brendel, Horst Hemmerle, Heinz-Werner Kleemann
-
Patent number: 6960594Abstract: A novel compound which inhibits certain integrins, particularly ?v integrins. Additionally, the novel compound may be used in a method of treating tumors or cancer which comprises administering a pharmaceutically effective amount of the compound to a patient. Additionally, the novel compound may be used in a method of inhibiting angiogensis. Finally, a method of producing the novel compound is disclosed.Type: GrantFiled: January 16, 2002Date of Patent: November 1, 2005Assignee: Shire BioChem Inc.Inventors: Denis Labrecque, Serge Lamothe, Marc Courchesne, Laval Chan, Giorgio Attardo, Karen Meerovitch
-
Patent number: 6916956Abstract: A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided.Type: GrantFiled: August 10, 2001Date of Patent: July 12, 2005Assignee: Japan Tobacco, Inc.Inventors: Yuko Shinagawa, Takeo Katsushima, Takashi Nakagawa
-
Patent number: 6835745Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, R3, X, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 10, 2003Date of Patent: December 28, 2004Assignee: WyethInventors: Richard D. Coghlan, William F. Fobare, Heather A. Harris, James C. Keith, Jr., Leo M. Albert
-
Publication number: 20040259875Abstract: An amine derivative, its tautomeric or stereoisomeric form, or a salt thereof which has vanilloid receptor 1 (VR1) antagonistic activity, is disclosed. The amine derivative has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.Type: ApplicationFiled: July 26, 2004Publication date: December 23, 2004Inventors: Takeshi Yura, Muneto Mogi, Yuka Ikegami, Tsutomu Masuda, Toshio Kokubo, Klaus Urbahns, Timothy B Lowinger, Nagahiro Yoshida, Joachim Freitag, Heinrich Meier, Reilinde Nopper, Makiko Marumo, Masahiro Shiroo, Masaomi Tajimi, Keisuke Takeshita, Toshiya Moriwaki, Yasuhiro Tsukimi
-
Publication number: 20040192758Abstract: The present invention relates to compounds of the general formula (II) and salts and physiologically functional derivatives thereof, 1Type: ApplicationFiled: December 17, 2003Publication date: September 30, 2004Applicant: 4SC AGInventors: Johann Leban, Stefan Tasler
-
Patent number: 6790866Abstract: The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is —COR1, —CH═CH—COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4). The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.Type: GrantFiled: July 30, 2002Date of Patent: September 14, 2004Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Shuichi Ohuchida, Yuuki Nagao
-
Patent number: 6790997Abstract: The invention relates to a process for the preparation of carbonyl compounds by the oxidation of alcohols in the presence of osmium compounds as catalysts in water or a solvent mixture containing water.Type: GrantFiled: July 23, 2002Date of Patent: September 14, 2004Assignee: Bayer AktiengesellschaftInventors: Markus Eckert, Hans-Christian Militzer, Matthias Beller, Christian Döbler, Gerald Mehltretter, Uta Sundermeier
-
Publication number: 20040106672Abstract: The present invention discloses compounds of Formula I. The present invention also discloses beta-3 agonists of formula I and methods for treating beta-3 mediated diseases and condition using the compounds of formula I, in particular methods for treating diabetes or obesity.Type: ApplicationFiled: July 31, 2003Publication date: June 3, 2004Inventors: David N. Deaton, Barry George Shearer, David Edward Uehling
-
Patent number: 6734207Abstract: Compounds are described that bind to tubulin causing tubulin depolymerization and inhibiting tubulin polymerization. The compounds of the invention are therapeutically effective to inhibit cellular proliferation, for example, as effective anti-cancer agents. The compounds can also induce cytotoxicity in cells such as leukemia cells. The chemical structure of the compounds includes a furan, thiophene, thiazole, oxazole, or imidazole group at one end of the molecule (head) and a hydrophobic, aliphatic chain at the other end of the molecule (tail).Type: GrantFiled: April 18, 2002Date of Patent: May 11, 2004Assignee: Parker Hughes InstituteInventors: Fatih M. Uckun, Shyi-Tai M. Jan
-
Publication number: 20040072871Abstract: A compound of formula (I) selected from: 1Type: ApplicationFiled: August 8, 2003Publication date: April 15, 2004Inventors: Anne-Claude Dublanchet, Delphine Compere, Philippe Cluzeau, Stephane Blais, Alexis Denis, Pierre Ducrot, Karine Courte, Sophie Descamps
-
Patent number: 6720425Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.Type: GrantFiled: December 9, 2002Date of Patent: April 13, 2004Assignee: Allergan, Inc.Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
-
Patent number: 6627652Abstract: Process of treatment of mammals, including humans to treat diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid receptor sites in preference to the RAR retinoid receptor sites. A compound is defined to be a selective agonist of the RXR receptor site if the compound is at least approximately ten times more effective as an agonist in the RXR receptor sites than in the RAR receptor sites.Type: GrantFiled: April 20, 1995Date of Patent: September 30, 2003Assignee: Allergan, Inc.Inventor: Roshantha A. S. Chandraratna
-
Patent number: 6566375Abstract: Compounds of this invention increase plasma levels of high density lipoprotein or HDL, the “good” cholesterol and as such may be useful for treating diseases such as atherosclerosis.Type: GrantFiled: April 26, 2001Date of Patent: May 20, 2003Assignee: WyethInventor: Thomas J. Commons